Quorexta

Quorexta is a healthcare provider in the Republic of Duquesne. (Quo-rex-tah) Quorexta LLC was founded in 1950 by 2 wealthy investors in the Verte Railroad Company, and in paving companies such as Perrier Paving, and the Terre-Moyenne Paving Company. The investors, Marques Le-Shen and David Penne, had accumulated massive amounts of wealth through investments in the construction of new train infrastructure for the Verte Railroad Company, which took place shortly after the Great War in 1935, and through government contracts in their paving business portfolio that constructed the majority of Duquesne's National Highway System. The pair formed the Executive Board of the company naming Penne the Chairman of the board after initial deliberations with other investors, and following the hiring of experienced military doctors who were experts in managing the healthcare program for the Duquesne Military, known as Military Health Services. The company began providing health insurance through partnerships with many hospital chains and local clinics. Over time, as the program became more popularly used, Quorexta began to buy out smaller, local healthcare companies, as well as clinics and hospital systems throughout Duquesne. This allowed them to cut the costs of healthcare, since they owned the various steps in the healthcare chain. By 1960, Quorexta owed about 55 percent of the healthcare industry in the Republic of Duquesne, which included a large number of research and drug manufacturing facilities, hospitals, insurance centers, and local offices and clinics. Scientists at Quorexta were able to research new drugs partnered with researchers from the Federation of Asteria. This partnership produced the world-renowned polio vaccine that eliminated the Asterian Polio Crisis of the late 1950s. In 1964, the founding chairman of Quorexta, David Penne, died at the age of 79. Coinciding with his death, Marques Le-Shen, now 76, announced his retirement from the board of Quorexta. The board chose James Shargue, head of the insurance division, to lead the company as CEO. Shargue quickly began a lobbying campaign to the Duquesne National Assembly to increase the freedom of patients with terminal illness to be able to use experimental drugs not yet verified by the Duquesne Surgeon General. After 5 years of deliberation and public lobbying, the Duquesne National Assembly passed the Right to Try Act of 1969, which allowed for the first time for patients with terminal illness to be able to use experimental drugs. Some critics argued that it just was a money handout to the increasing monopoly in the medical industry, but overwhelming public support was behind the issue.